Myocardial ¹²³I-MIBG Uptake and Cardiovascular Autonomic Function in Parkinson’s Disease

Table 1

Correlation between disease parameters and MIBG scintigraphy or autonomic function tests.

	Disease duration; ( value)	H&Y; ( value)	LEDD; ( value)
MIBG scintigraphy
Early H/M ratio	−0.10 (0.49)	−0.14 (0.32)	0.07 (0.63)
Late H/M ratio	−0.06 (0.66)	−0.15 (0.31)	0.11 (0.45)
Washout rate	0.04 (0.81)	0.19 (0.20)	−0.03 (0.85)
Autonomic function tests
HRV
LF component	−0.11 (0.44)	−0.08 (0.60)	−0.08 (0.57)
HF component	−0.26 (0.07)	−0.20 (0.17)	−0.17 (0.25)
LF/HF ratio	0.16 (0.28)	0.09 (0.55)	0.11 (0.43)
CV	−0.11 (0.49)	−0.09 (0.32)	−0.06 (0.68)
HUT test
SBP change	0.03 (0.84)	−0.04 (0.78)	0.00 (0.98)
DBP change	0.18 (0.22)	0.10 (0.50)	0.08 (0.58)
HR change	0.09 (0.52)	−0.12 (0.43)	0.12 (0.39)

Data are represented as Spearman correlation coefficients. H&Y, Hoehn and Yahr stage; LEDD, L-dopa equivalent daily dose; MIBG, ¹²³I-metaiodobenzylguanidine myocardial scintigraphy; H/M ratio, heart to mediastinum ratio; HRV, heart rate variability; LF, low-frequency; HF, high-frequency; CV, coefficient of variation of R-R intervals; HUT, head-up tilt; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.